The lowest suggested price for a course from Sinovac, the newspaper writes, is $ 21. Ukraine ordered it at $ 17.85 per dose. The course is two doses.
The most expensive vaccine that is already available or will soon be available for orders is the development of the Chinese company Sinopharm: over $ 30 per dose. Then, in order of decreasing cost, there are drugs from Pfizer-BNT, Moderna, Sinovac and CureVac.
The lowest prices are at the Bharat Biotech Indians, the better known Oxford / AstraZeneca, as well as the Russian Sputnik-5.
The situation with the exact prices for drugs from Novavax (one dose needed) and J&J (two doses needed) remains unclear. They will probably be in the region of $ 10 per course.
Below are the average prices per dose for a variety of vaccines as of February 3. The authors clarify that prices were not available for all purchases or sales revenues. MIC – middle-income countries, HIC – wealthy countries, PAHO – Pan American Health Organization, self-procuring – direct purchases of countries from the manufacturer:
A table showing the known sources and amounts of funding for the development and production of vaccines:
As you can see, the latest RNA drugs from Moderna and Pfizer-BNT are not the leaders, judging by the “infusions” that are known about. First on this list are vaccines from Sanofi / GSK and Novavax: more than $ 2 billion in funding each.
The huge funds that companies, governments, and non-governmental organizations have thrown after the appearance of SARS-CoV-2 in humans to create vaccines for COVID-19 is one of the reasons for the extraordinarily short time frame for their development and testing.
Below is a graph of the readiness of the population of different countries to be vaccinated against coronavirus. Vietnam is the clear leader, followed by India, China, Denmark, and South Korea.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
